Balyasny Asset Management’s Cogent Biosciences COGT Stock Holding History

Balyasny Asset Management’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$33M	Sell	856,598 -583,720	-41%	-$21.6M	0.04%	495
2025 Q4	$51.2M	Sell	1,440,318 -1,230,168	-46%	-$34.6M	0.06%	350
2025 Q3	$38.3M	Buy	+2,670,486	New	+$31.6M	0.05%	456
2025 Q2	–	Sell	-109,003	Closed	-$653K	–	2894
2025 Q1	$653K	Buy	109,003 +88,198	+424%	+$691K	﹤0.01%	2179
2024 Q4	$162K	Buy	20,805 +1,687	+9%	+$16.8K	﹤0.01%	2555
2024 Q3	$206K	Sell	19,118 -25,323	-57%	-$247K	﹤0.01%	2554
2024 Q2	$375K	Buy	+44,441	New	+$337K	﹤0.01%	2159
2023 Q4	–	Sell	-125,638	Closed	-$1.22M	–	2544
2023 Q3	$1.22M	Buy	+125,638	New	+$1.49M	﹤0.01%	1513
2023 Q2	–	Sell	-19,974	Closed	-$216K	–	2342
2023 Q1	$216K	Buy	+19,974	New	+$255K	﹤0.01%	2205
2022 Q4	–	Sell	-1,049,542	Closed	-$15.7M	–	2837
2022 Q3	$15.7M	Sell	1,049,542 -51,761	-5%	-$709K	0.05%	511
2022 Q2	$9.93M	Buy	+1,101,303	New	+$7.52M	0.03%	652

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Balyasny Asset Management's COGT Position: Q1 2026 in Review

Balyasny Asset Management reduced its Cogent Biosciences (COGT) stake by 41% in Q1 2026, selling an estimated $21.6M and leaving 856,598 shares worth $33M. The position accounts for 0.04% of the portfolio, ranked #495.

Balyasny Asset Management first reported a position in COGT in Q2 2022 and has held it in 11 quarters since. The position peaked at $51.2M in Q4 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

Balyasny Asset Management held 856,598 shares of Cogent Biosciences worth $33M as of Q1 2026.
Balyasny Asset Management sold 583,720 Cogent Biosciences shares in Q1 2026, an estimated $21.6M.
Cogent Biosciences made up 0.04% of Balyasny Asset Management's portfolio in Q1 2026, its #495 holding.
Balyasny Asset Management first reported a position in Cogent Biosciences in Q2 2022 and has held it in 11 quarters since.
Balyasny Asset Management's Cogent Biosciences position peaked at $51.2M in Q4 2025.
305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.